HLA class I expression and ratios as diagnostic and predictive biomarkers in hepatocellular carcinoma: A multi-omics study

Background Human leukocyte antigen class I (HLA-I) genes, including HLA-A, HLA-B, and HLA-C, are essential for immune responses against hepatocellular carcinoma (HCC) by presenting peptides to cytotoxic T lymphocytes. This study aimed to investigate the diagnostic and predictive value of HLA-I genes in HCC through the integration of bulk and single-cell RNA sequencing, spatial transcriptomics, and mutational profiling. Materials and methods Bulk RNA-seq and microarray datasets were analyzed to assess differential expression, clinical associations, survival outcomes, and diagnostic potential of HLA-I genes. Single-cell RNA sequencing data were integrated to evaluate cell-type-specific expression patterns, co-expression dynamics, and immune evasion using pseudo-bulk approaches. Spatial transcriptomics was analyzed at both pooled and patient levels to characterize compartment-specific heterogeneity. Additionally, allele-specific expression and peptide-MHC binding affinities were examined, and somatic mutation profiles of HLA-I and antigen-processing machinery genes were obtained from The Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Comprehensive statistical and modeling analyses were performed to ensure robust evaluation across datasets. Results Elevated HLA-I expression levels and expression ratios were associated with advanced clinicopathological features. Higher HLA-A/HLA-B expression ratios correlated with poor clinical outcomes. HLA-I gene expression was higher in Sorafenib non-responders, whereas the expression ratios showed divergent patterns: HLA-A/HLA-B was lower, while HLA-A/HLA-C and HLA-B/HLA-C were higher in non-responders. In a separate diagnostic analysis distinguishing HCC from non-tumor liver tissue, the combined model incorporating all three HLA-I expression ratios achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 0.90. Single-cell RNA sequencing revealed reduced HLA-I expression in most tumor microenvironment cell types, with a subset of malignant cells showing apparent loss of expression. Expression dysregulation and binding affinity differences were observed among high-prevalence HLA-I alleles. Mutation analysis indicated that approximately 7% of patients harbor non-synonymous alterations in HLA-I or antigen-processing machinery genes. Additional evaluation demonstrated stable predictive performance and clinical utility beyond ROC-based discrimination. Conclusion HLA-I gene expression patterns, expression ratios, and mutation status show potential as diagnostic and predictive biomarkers of Sorafenib response in HCC patients, highlighting their relevance for precision oncology applications.

Authors

Institutions

Publication Details

Journal
Heliyon
Published
2026-11-12
DOI
https://doi.org/10.1016/j.heliyon.2026.e45617
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

HLA class I expression and ratios as diagnostic and predictive biomarkers in hepatocellular carcinoma: A multi-omics study

Shahram Aliyari, Benedikt Brors, Mohammad Hossein Norouzi‐Beirami, Kaveh Kavousi et al.
Heliyon
Cancer Immunotherapy and Biomarkers
article

HLA class I expression and ratios as diagnostic and predictive biomarkers in hepatocellular carcinoma: A multi-omics study

Shahram Aliyari, Benedikt Brors, Mohammad Hossein Norouzi‐Beirami, Kaveh Kavousi, Zahra Salehi
article en

Abstract

Background Human leukocyte antigen class I (HLA-I) genes, including HLA-A, HLA-B, and HLA-C, are essential for immune responses against hepatocellular carcinoma (HCC) by presenting peptides to cytotoxic T lymphocytes. This study aimed to investigate the diagnostic and predictive value of HLA-I genes in HCC through the integration of bulk and single-cell RNA sequencing, spatial transcriptomics, and mutational profiling. Materials and methods Bulk RNA-seq and microarray datasets were analyzed to assess differential expression, clinical associations, survival outcomes, and diagnostic potential of HLA-I genes. Single-cell RNA sequencing data were integrated to evaluate cell-type-specific expression patterns, co-expression dynamics, and immune evasion using pseudo-bulk approaches. Spatial transcriptomics was analyzed at both pooled and patient levels to characterize compartment-specific heterogeneity. Additionally, allele-specific expression and peptide-MHC binding affinities were examined, and somatic mutation profiles of HLA-I and antigen-processing machinery genes were obtained from The Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Comprehensive statistical and modeling analyses were performed to ensure robust evaluation across datasets. Results Elevated HLA-I expression levels and expression ratios were associated with advanced clinicopathological features. Higher HLA-A/HLA-B expression ratios correlated with poor clinical outcomes. HLA-I gene expression was higher in Sorafenib non-responders, whereas the expression ratios showed divergent patterns: HLA-A/HLA-B was lower, while HLA-A/HLA-C and HLA-B/HLA-C were higher in non-responders. In a separate diagnostic analysis distinguishing HCC from non-tumor liver tissue, the combined model incorporating all three HLA-I expression ratios achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 0.90. Single-cell RNA sequencing revealed reduced HLA-I expression in most tumor microenvironment cell types, with a subset of malignant cells showing apparent loss of expression. Expression dysregulation and binding affinity differences were observed among high-prevalence HLA-I alleles. Mutation analysis indicated that approximately 7% of patients harbor non-synonymous alterations in HLA-I or antigen-processing machinery genes. Additional evaluation demonstrated stable predictive performance and clinical utility beyond ROC-based discrimination. Conclusion HLA-I gene expression patterns, expression ratios, and mutation status show potential as diagnostic and predictive biomarkers of Sorafenib response in HCC patients, highlighting their relevance for precision oncology applications.

HeliyonVol. 12(17)
German Cancer Research Center (DE), University of Tehran (IR), Hamedan University of Technology (IR), Tehran University of Medical Sciences (IR)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon